Platinum-based antineoplastic drug

"Platinum analog" does not denote a single, specific molecule or receptor, but instead refers collectively to a class of chemotherapeutic agents known as "platinum-based antineoplastic drugs". These pharmaceuticals, including cisplatin, carboplatin, and oxaliplatin, are coordination complexes of platinum and function as cytotoxic agents used in cancer treatment. Their primary mechanism is to form crosslinks with DNA in tumor cells, thereby inhibiting replication and transcription, which leads to cell death[1][3][5]. The term "platinum analog" thus represents a drug class rather than a molecular target, receptor, or protein, meaning it is not a therapeutic target in itself but is a descriptor of structurally related drugs developed for improved efficacy and reduced toxicity over the original agent, cisplatin[1][5].\n\nBecause "Platinum analog" is not a biomolecule or receptor, most fields from your schema—such as canonical full name, abbreviation, molecular classification, mechanism of action, biomarkers, and therapeutic targeting—do not directly apply. Platinum analogs act on DNA and may bind macromolecules nonspecifically, but the term itself does not specify a particular binding partner or druggable protein target[5][7].

Other names

Platinum analogplatinum-based anticancer drugplatinum-based chemotherapyplatins